Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment
Azab, H., Shawky, S., El-Sheikh, M., Ebeid, E., abd-elhamid, A., shalaby, S., Elshal, A. (2024). Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment. EKB Journal Management System, 8(2), 1-14. doi: 10.21608/jcbr.2024.236764.1315
Hoor Mohamed Azab; Sherif M Shawky; Mohamed M El-Sheikh; El-Zeiny M Ebeid; Abdelhamid abd-elhamid; sally shalaby; Amal Elshal. "Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment". EKB Journal Management System, 8, 2, 2024, 1-14. doi: 10.21608/jcbr.2024.236764.1315
Azab, H., Shawky, S., El-Sheikh, M., Ebeid, E., abd-elhamid, A., shalaby, S., Elshal, A. (2024). 'Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment', EKB Journal Management System, 8(2), pp. 1-14. doi: 10.21608/jcbr.2024.236764.1315
Azab, H., Shawky, S., El-Sheikh, M., Ebeid, E., abd-elhamid, A., shalaby, S., Elshal, A. Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment. EKB Journal Management System, 2024; 8(2): 1-14. doi: 10.21608/jcbr.2024.236764.1315

Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment

Egyptian Journal of Cancer and Biomedical Research
Volume 8, Issue 2, June 2024, Page 1-14  XML PDF (6.63 MB)
Document Type: Original Article
DOI: 10.21608/jcbr.2024.236764.1315
View on SCiNiTO View on SCiNiTO
Authors
Hoor Mohamed Azab email 1; Sherif M Shawky2; Mohamed M El-Sheikh1; El-Zeiny M Ebeid1; Abdelhamid abd-elhamid3; sally shalaby4; Amal Elshal4
1Chemistry Department Faculty of Science, Tanta University
2Misr University for Science and Technology, Egypt
3chemistry department, faculty of science, Tanta University
4Medical Biochemistry Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt
Abstract
Doxorubicin (DOX) as one of the main chemotherapies used in breast cancer in the form of many dosage forms such as encapsulation within pegylated liposomes and by injection. Both dosage forms have several side effects, most importantly dilated cardiomyopathy, erythema, acral erythema, and others. Also, DOX acquires resistance in dose-dependent manner by time. Consequently, there is an urgent need for novel approaches and strategies to improve current chemotherapeutic agents’ delivery systems including DOX. Nanoparticles (NPs) have found their way in almost all aspects of biomedical applications within the last two decades, such as medical diagnostics, imaging, and drug/gene delivery systems. Mesoporous silica NPs are of great interest as an efficient drug/gene delivery system due to their unique properties. In the same context, magnetic nanoparticles contributed significantly to biomedicine, for their apparent features emerging at the nanoscale. Core/shell nanoparticles have potential characteristics as they incorporate the multiple merits of the used nanoparticles. Herein, we have developed multifunctional iron oxide/mesoporous silica/amino; core/shell (M/silica/Amino), by sonochemical method, loaded with DOX as a Drug Delivery System (DDS) for breast cancer treatment.
Keywords
Doxorubicin (DOX); iron oxide/mesoporous silica/amino core/shell (M@silica@Amino); drug delivery system; and breast cancer; Cell lines
Statistics
Article View: 278
PDF Download: 335